Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals

Author

  • J. O. Lagerstedt
  • J. Dalla-Riva
  • G. Marinkovic
  • R. Del Giudice
  • D. Engelbertsen
  • J. Burlin
  • J. Petrlova
  • M. Lindahl
  • K. Bernfur
  • O. Melander
  • J. Nilsson
  • A. Schiopu

Summary, in English

Objective: IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively associated with carotid artery disease progression and with the risk for first-time cardiovascular events in individuals with no previous history of cardiovascular disease. Approach and results: We selected 383 subjects from the cardiovascular cohort of Malmö Diet and Cancer study who suffered a coronary event during a median follow-up period of 15.4 (10.3–16.4) years and 395 age- and sex-matched controls. None of the study participants had a previous history of coronary artery disease or stroke. Anti-ApoA-I IgG were measured by ELISA in serum samples collected at baseline. Intima-media thickness (IMT) was measured in the common carotid artery and in the carotid bifurcation at baseline and after 15.9 (±1.5) years. We found no associations between anti-ApoA-I IgG and carotid artery IMT at baseline or with IMT progression during follow-up. In Cox proportional hazards analyses adjusted for traditional cardiovascular risk factors, the hazard ratio (HR 95%CI) for the primary outcome, incident coronary events, was 0.97 (0.75–1.25), P = 0.782, in subjects with anti-ApoA-I IgG within the highest tertile compared with the lowest tertile. Similarly, we did not find any associations with the secondary outcome, incident first-time stroke. Conclusions: Serum autoantibodies against ApoA-I do not correlate with disease progression and adverse events in cardiovascular disease-free individuals from the general population.

Department/s

  • Medical Protein Science
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Genetic and Molecular Epidemiology
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Glucose Transport and Protein Trafficking
  • Biochemistry and Structural Biology
  • Cardiovascular Research - Hypertension
  • EpiHealth: Epidemiology for Health
  • Department of Clinical Sciences, Lund

Publishing year

2019-01

Language

English

Pages

49-58

Publication/Series

Journal of Internal Medicine

Volume

285

Issue

1

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • apolipoprotein A-I
  • autoantibodies
  • carotid intima-media thickness
  • coronary artery disease
  • HDL

Status

Published

Research group

  • Medical Protein Science
  • Genetic and Molecular Epidemiology
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Glucose Transport and Protein Trafficking
  • Cardiovascular Research - Hypertension

ISBN/ISSN/Other

  • ISSN: 0954-6820